<DOC>
	<DOCNO>NCT01017276</DOCNO>
	<brief_summary>This multi-center , open-labeled , non-comparative study examine safety efficacy ASP1585 chronic kidney disease hyperphosphatemia patient peritoneal dialysis .</brief_summary>
	<brief_title>A Phase 3 Study Patients With Chronic Kidney Disease Hyperphosphatemia Peritoneal Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Chronic kidney disease patient peritoneal dialysis Hyperphosphatemia Patients phosphate binder phosphate lower drug 28 day longer , , dose change within 28 day . Written informed consent Patients gastrointestinal surgery enterectomy Patients severe cardiac disease Patients severe constipation diarrhea Patients history complication malignant tumor Patients uncontrolled hypertension Patients treat parathyroid intervention</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Hyperphosphatemia</keyword>
	<keyword>Peritoneal dialysis</keyword>
	<keyword>CKD</keyword>
	<keyword>ASP1585</keyword>
</DOC>